LOVENOX
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
May 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
Priority Review
LOVENOX by Sanofi is properties. Approved for deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): in patients undergoing abdominal surgery, during and 3 more indications. First approved in 2007.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOVENOX (enoxaparin) is an injectable anticoagulant that prevents blood clots by enhancing inhibition of Factor Xa and thrombin through antithrombin. It is indicated for prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) across multiple surgical and medical settings, including abdominal surgery, knee replacement, and acute coronary syndromes.
$653KPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with declining Medicare spending, signaling shrinking brand team resources and transition focus to generic or lifecycle extension strategies.
Mechanism of Action
properties.
Worked on LOVENOX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.